The family of G protein-coupled receptors (GPCRs) is the largest class of membrane
proteins and an important drug target due to their role in many (patho) physiological …

Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous
tumors, including breast, gastric, and various other solid tumors. While anti-HER2 therapies …

HER2-positive breast cancer, an aggressive cancer, is treated with combinations of
conventional anticancer drugs viz., cytotoxic drugs, nibs, and mAbs. Major limitations …

Over the last decades, monoclonal antibodies have substantially improved the treatment of
several conditions. The continuous search for novel therapeutic targets and improvements in …

Cancer is the most acute disease and the leading cause of patient death worldwide. Both
chemotherapy and molecular-based therapies play an important role in curing cancer …

Human epidermal growth factor receptor 2 (HER2) protein overexpression is found in~ 30%
of invasive breast carcinomas and in a high proportion of noninvasive ductal carcinomas in …

Overexpression of human epidermal growth factor receptor type 2 (HER2) is considered as
a prognostic factor of breast cancer, which is positively associated with recurrence when …

Solid cancers are affiliate on angiogenesis for preservation. The FDA-approved monoclonal
antibodies like Bevacizumab are currently being administered effectively as inhibitors of …

Members of the Camelidae have unique adaptive immunological features that are not widely
observed in other species. All camelids are known to have three distinct IgG isotypes–IgG1 …

Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are
associated with aggressive tumor growth and poor clinical outcomes. Bispecific antibodies …